Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003545 · ClinicalTrials.gov registry record · Phase 2
506U78 in Treating Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
A Phase 2 study of Lymphoma and Leukemia, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
- 20
- Study locations
NCT00003545: Completed Phase 2 study of Lymphoma and Leukemia, sponsored by National Cancer Institute (NCI).
NCT00003545 is a Phase 2 study of Lymphoma and Leukemia that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 35 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (93% lower). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003545, a Phase 2 study of Lymphoma and Leukemia, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
- 20
- Study locations
Study Summary
Phase II trial to study the effectiveness of 506U78 in treating patients with refractory or relapsed acute lymphoblastic leukemia or lymphoblastic lymphoma. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
Interventions
- DRUG nelarabine
Study Locations (20)
California
- Cancer Center and Beckman Research Institute, City of Hope - Duarte
- Veterans Affairs Medical Center - Long Beach - Long Beach
- USC/Norris Comprehensive Cancer Center and Hospital - Los Angeles
- Veterans Affairs Medical Center - West Los Angeles - Los Angeles
- Jonsson Comprehensive Cancer Center, UCLA - Los Angeles
- Veterans Affairs Outpatient Clinic - Martinez - Martinez
- CCOP - Bay Area Tumor Institute - Oakland
- Chao Family Comprehensive Cancer Center - Orange
- University of California Davis Medical Center - Sacramento
- CCOP - Santa Rosa Memorial Hospital - Santa Rosa
- Stanford University - Stanford
- David Grant Medical Center - Travis Air Force Base
Arizona
- CCOP - Greater Phoenix - Phoenix
- Veterans Affairs Medical Center - Phoenix (Hayden) - Phoenix
- Veterans Affairs Medical Center - Tucson - Tucson
- Arizona Cancer Center - Tucson
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
- Veterans Affairs Medical Center - Little Rock (McClellan) - Little Rock
Alabama
- MBCCOP - Gulf Coast - Mobile
Colorado
- University of Colorado Cancer Center - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 1998-08 |
| Phase | Phase 2 |
What the finished NCT00003545 record still lists
NCT00003545 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (93% lower).
The record links to 2 conditions, with Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which nelarabine is the first listed.
NCT00003545 names 20 study sites across 5 states, led by California, Arizona, Arkansas.
Frequently Asked Questions
What is clinical trial NCT00003545 about?
NCT00003545 is a clinical study titled "506U78 in Treating Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma". Phase II trial to study the effectiveness of 506U78 in treating patients with refractory or relapsed acute lymphoblastic leukemia or lymphoblastic lymphoma. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
What is the current status of trial NCT00003545?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 1998-08.
What conditions does trial NCT00003545 study?
This clinical trial studies the following conditions: Lymphoma, Leukemia.
What interventions are being tested in trial NCT00003545?
The interventions under investigation include: nelarabine (DRUG).
Who is sponsoring clinical trial NCT00003545?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00003545 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00003545's enrollment target sits among peer trials
35 196th of 299 higher than 98 of 299 other Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
RECRUITING · Phase 2
-
Odronextamab in Low Tumor Volume Advanced FL
RECRUITING · Phase 2
-
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
RECRUITING · Phase 2
-
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
RECRUITING · Phase 2
-
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia